Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
Tiziana Life Sciences reported positive PET imaging results from the third Multiple System Atrophy (MSA) patient treated with intranasal foralumab in a Phase 2 trial, showing up to a 34% reduction in standardized uptake value (SUV). The new data aligns with findings from the first two patients, demonstrating consistent reductions in neuroinflammation across clinically relevant brain regions such as the basal ganglia and cerebellar white matter.
Key figures
- Drug Name
- Intranasal Foralumab
- Phase Of Trial
- Phase 2
- Suv reduction pct
- 34%
- Suvr reduction pct
- 26%
- Cohort avg suv reduction pct
- ~35%
- Cohort avg suvr reduction pct
- 24%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.